Why Rapt Therapeutics Stock Soared Today

GSK agreed to acquire Rapt Therapeutics for $2.2 billion ($58.00/share), representing a premium of over 65% to Rapt's closing price on Jan. 16, and Rapt shares jumped more than 60% on the announcement. The deal gives GSK global rights to ozureprubart outside mainland China, Macau, Taiwan and Hong Kong; the antibody is in Phase 2 and targets a protein linked to roughly 94% of severe food allergies amid an addressable US population of ~17 million (1.3 million with severe reactions). The transaction is expected to close in the first quarter, subject to regulatory approval, and materially enhances GSK’s immunology pipeline exposure.

Analysis

Market structure: RAPT shareholders are the clear near-term winners (65%+ takeover premium to Jan 16), while small-cap allergy-focused biotechs face a two-week–to–several‑month rerating as acquirers and investors reprice M&A optionality. GSK gains incremental pricing power and a potential high‑margin biologic addressing ~17M US patients; if ozureprubart reaches market, peak sales could meaningfully exceed $1–3bn annually versus current guidance for comparable biologics, shifting payer negotiations. Credit/FX: expect a modest widening in GSK credit spreads if cash/debt finances the deal and a mild GBP/USD reaction to acquisition headlines; RAPT equity vols should collapse toward merger‑arb levels, reducing options premia.

Risk assessment: Primary tail risks are regulatory or Phase‑3/confirmatory failure (assign ~25–35% combined probability over 12–36 months) and deal closing delays beyond Q1 which would widen arbitrage spreads. Hidden dependencies include China carve‑out (RAPT retains mainland China rights), creating detached upside that could be monetized later and complicate global commercial roll‑out; integration prioritization at GSK could delay development or trigger writedowns. Key catalysts: deal close (expected Q1), Phase‑2/3 readouts (6–18 months), and any China partnership announcements (30–180 days).

Trade implications: Execute merger‑arb in RAPT only when spread to $58 >1.5% — target 3–5% portfolio allocation with stop if spread widens >5% or regulatory denial occurs; hedge with a small long‑dated put on GSK to protect macro shock. For strategic upside, establish a tactical GSK overweight: 9–15 month call‑spread (buy 15% OTM / sell 35% OTM) sized 1–2% of portfolio to capture re‑rating if ozureprubart de‑risking occurs. Rotate 200–300bps from small‑cap biotech into large‑cap pharma (GSK, PFE) to reduce binary volatility.

Contrarian angles: The market underestimates both downside if ozureprubart fails (leading to >20–40% negative revaluation of the deal consideration) and upside locked in China as an independent asset; consensus treats the $58 as near‑certainty despite Phase‑2 stage. Historical parallels (big‑pharma bolt‑on buys later written down) suggest sizing conservatively; an overpay by GSK could prompt margin and capital reallocation that depresses near‑term TSR. Watch for unintended consequences: China carve‑out enabling a faster local competitor or partner commercialization that fragments global pricing and reduces GSK’s projected peak revenue.

Key Decisions for Investors

• Merger arbitrage RAPT (RAPT): establish a 3–5% long position if market price ≤ $57 (implied spread ≥1.7% to $58), target close in Q1; set stop/exit if spread widens >5% or any adverse regulatory announcement; size exposures so maximum loss equals 1% portfolio.
• Tactical GSK (GSK) upside via options: purchase a 9–15 month call spread sized 1–2% of portfolio (buy ~15% OTM / sell ~35% OTM) to capture pipeline re‑rating on positive ozureprubart de‑risking; roll or liquidate on >20% move or at 12 months.
• Relative value: short DBV Technologies (DBVT) equal notional to 1% of portfolio versus a 1–2% GSK long (pairs trade) — rationale: DBV is higher binary clinical risk in the allergy space and likely to underperform large‑cap acquirer post‑M&A rerate; tighten stop at 10% adverse move.
• Portfolio tilt: rotate 200–300bps from small‑cap biotech into large‑cap pharma (e.g., GSK, PFE) over next 30 days to reduce binary exposure and capture consolidation benefits; avoid initiating new small‑cap allergy long positions until ozureprubart Phase‑2/3 efficacy readouts (expected 6–12 months).